Your browser doesn't support javascript.
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
Lyke, Kirsten E; Atmar, Robert L; Islas, Clara Dominguez; Posavad, Christine M; Szydlo, Daniel; Paul Chourdhury, Rahul; Deming, Meagan E; Eaton, Amanda; Jackson, Lisa A; Branche, Angela R; El Sahly, Hana M; Rostad, Christina A; Martin, Judith M; Johnston, Christine; Rupp, Richard E; Mulligan, Mark J; Brady, Rebecca C; Frenck, Robert W; Bäcker, Martín; Kottkamp, Angelica C; Babu, Tara M; Rajakumar, Kumaravel; Edupuganti, Srilatha; Dobrzynski, David; Coler, Rhea N; Archer, Janet I; Crandon, Sonja; Zemanek, Jillian A; Brown, Elizabeth R; Neuzil, Kathleen M; Stephens, David S; Post, Diane J; Nayak, Seema U; Suthar, Mehul S; Roberts, Paul C; Beigel, John H; Montefiori, David C.
  • Lyke KE; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: klyke@som.umaryland.edu.
  • Atmar RL; Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA. Electronic address: ratmar@bcm.edu.
  • Islas CD; Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Posavad CM; Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Departments of Laboratory Medicine and Pathology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Szydlo D; Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Paul Chourdhury R; Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Deming ME; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Eaton A; Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Branche AR; Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, NY, USA.
  • El Sahly HM; Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA.
  • Rostad CA; Department of Pediatrics and Center for Childhood Infections and Vaccines, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Martin JM; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Johnston C; Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Departments of Laboratory Medicine and Pathology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Was
  • Rupp RE; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
  • Mulligan MJ; NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
  • Brady RC; Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Frenck RW; Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Bäcker M; NYU Langone Hospital-Long Island Vaccine Center Research Clinic and Division of Infectious Disease, Department of Medicine, NYU Long Island School of Medicine, Mineola, NY, USA.
  • Kottkamp AC; NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
  • Babu TM; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Rajakumar K; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Edupuganti S; Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Hope Clinic of Emory Vaccine Center, Atlanta, GA, USA.
  • Dobrzynski D; Department of Medicine, Division of Infectious Diseases, University of Rochester, Rochester, NY, USA.
  • Coler RN; Seattle Children's Research Institute, University of Washington School of Medicine, Seattle, WA, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
  • Archer JI; FHI360, Durham, NC 27701, USA.
  • Crandon S; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Zemanek JA; Statistical Center for HIV/AIDS Research and Prevention (SCHARP), University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Brown ER; Vaccine and Infectious Disease Division, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Stephens DS; Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Post DJ; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Nayak SU; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Suthar MS; Emory Vaccine Center, Yerkes National Primate Research Center, Department of Pediatrics, Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA.
  • Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Beigel JH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Montefiori DC; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: monte@duke.edu.
Cell Rep Med ; 3(7): 100679, 2022 07 19.
Article in English | MEDLINE | ID: covidwho-1895507
ABSTRACT
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2. This trial was conducted under ClincalTrials.gov NCT04889209.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article